HighTower Advisors
DFTX

HighTower Advisors’s Definium Therapeutics DFTX Stock Holding History

HighTower Advisors’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,733
Closed -$30K – 3336
2021
Q2 		$30K Buy
+1,733
New +$91K ﹤0.01% 2931

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HighTower Advisors's DFTX Position: Q1 2026 in Review

HighTower Advisors opened a new position in Definium Therapeutics (DFTX) in Q1 2026: 18,559 shares worth $351K. The stake represents ﹤0.01% of the portfolio and ranks #3021 among its holdings. This is a return to the name: HighTower Advisors previously reported a position in DFTX as recently as Q3 2025.

HighTower Advisors first reported a position in DFTX in Q2 2021 and has held it in 11 quarters since. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

  • HighTower Advisors held 18,559 shares of Definium Therapeutics worth $351K as of Q1 2026.
  • Definium Therapeutics was a new HighTower Advisors position in Q1 2026.
  • Definium Therapeutics made up ﹤0.01% of HighTower Advisors's portfolio in Q1 2026, its #3021 holding.
  • HighTower Advisors first reported a position in Definium Therapeutics in Q2 2021 and has held it in 11 quarters since.
  • 247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on HighTower Advisors's 13F filing for Q1 2026, filed 5 May 2026.